EricISbarDO

Oncology • Collegeville, PA

Thoracic Cancer

Senior Medical Director

Join to view full profile

Dr. Sbar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sbar's full profile

Already have an account?

Office
500 Arcola Road
Collegeville, PA 19426
Phone+1 484-865-4147
Is this information wrong?

Summary

I have worked in the pharmaceutical industry for 10+ years developing small molecule and immune checkpoint inhibitors in lung cancer

Clinical Expertise

Immunotherapy, Thoracic oncology, Gene Targeting, Receptor Protein-Tyrosine Kinases

Education & Training

Cooper Medical School of Rowan University/Cooper University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001
Abington Memorial HospitalResidency, Internal Medicine, 1995 - 1998
Temple UniversityB.A., 1998
Philadelphia College of Osteopathic MedicineClass of 1994

Awards, Honors, & Recognition

Golden Apple Teaching Award UMDNJ - Camden Campus, 2001

Clinical Trials

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer Start of enrollment: 2011 Jun 16
Completed
Phase 3
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Start of enrollment: 2011 Dec 26
Completed
Phase 2
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. Start of enrollment: 2013 May 09
Completed
Phase 3
A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
A Rollover Protocol of Dacomitinib For Patients In Japan Start of enrollment: 2015 Jul 10
Completed
Phase 2
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) Start of enrollment: 2015 Dec 18
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

9 citations
Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.
Qing Zhou, Yi-Long Wu, Jesus Corral, Kazuhiko Nakagawa, Edward B. Garon, Eric Sbar, Tao Wang, Rickard Sandin, Kay Noonan, Diana Gernhardt, Tony Mok> ;Future Oncology. 2019 Mar 6
307 citations
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating...
Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Min Lee, R. Linke, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam Pluzans...> ;Journal of Clinical Oncology. 2018 Jun 4
9 citations
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers
Helena A. Yu, Myung-Ju Ahn, Byoung Chul Cho, David E. Gerber, Ronald B. Natale, Mark A. Socinski, Nagdeep Giri, Susan Quinn, Eric Sbar, Hui Zhang, Giuseppe Giaccone> ;Lung Cancer. 2017 Oct 1
714 citations
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase...
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, R. Linke, Rafael Rosell, Jesus Corral, Maria Rita Migliorino, Adam ...> ;The Lancet. Oncology. 2017 Nov 1
46 citations
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lu...
Mario E. Lacouture, Dorothy M. K. Keefe, Stephen T. Sonis, Aminah Jatoi, Diana Gernhardt, Tao Wang, Jim P. Doherty, Nagdeep Giri, Sashi Nadanaciva, Joe O'Connell, Eric...> ;Annals of Oncology. 2016 Sep 1
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ramalingam SS, O'Byrne K, Boyer M, Mok T, Jänne PA, Zhang H, Liang J, Taylor I, Sbar EI, Paz-Ares L> ;Ann. Oncol.. 2016-07-01
11 citations
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
S S Ramalingam, K O'Byrne, M Boyer, T Mok, P A Jänne, H Zhang, J Liang, I Taylor, E I Sbar, L Paz-Ares> ;Annals of Oncology. 2016 Mar 1
2 citations
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic s...
Laura Q.M. Chow, Grace K. Dy, Garth Nicholas, Catherine Fortin, Daniel Patricia, Alex A. Adjei, Chandra P. Belani, Ashok Kumar Gupta, Jong Soon Park, Steven Zhang, Eri...> ;Cancer Chemotherapy and Pharmacology. 2013 Mar 7
2 citations
Phase I Study of Sequential Administration of Topotecan and 5-Fluorouracil in Patients with Advanced Malignancies
Eric I. Sbar, Jamil Khatri, W. David Rodman, Lori Tritschler, Jack Goldberg, Generosa Grana, Linda Devereux, Alexandre Hageboutros> ;Cancer Investigation. 2002 Jul 17
Join now to see all

Research History

Medical Director - Bristol-Myers Squibb2007 - 2013

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member
European Society of Medical Oncology
Member
International Association for the Study of Lung Cancer
Member
Society of Immunotherapy in Cancer
Member